Welcome to our dedicated page for Celldex Therapeutics news (Ticker: CLDX), a resource for investors and traders seeking the latest updates and insights on Celldex Therapeutics stock.
Celldex Therapeutics, Inc. (NASDAQ: CLDX) generates frequent news as it advances antibody-based therapies in immunology, with a particular emphasis on mast cell–driven diseases. Company updates often center on barzolvolimab, a humanized monoclonal antibody targeting the KIT receptor on mast cells, and CDX-622, a bispecific antibody that neutralizes thymic stromal lymphopoietin (TSLP) and depletes mast cells via stem cell factor (SCF) starvation.
News coverage for Celldex commonly includes clinical trial milestones across multiple indications. For barzolvolimab, the company reports data from Phase 2 studies in chronic spontaneous urticaria (CSU) and chronic inducible urticarias such as cold urticaria (ColdU) and symptomatic dermographism (SD), describing statistically significant improvements in urticaria activity scores, provocation tests and quality-of-life measures, along with favorable safety profiles. Investors and clinicians can also follow announcements about the global Phase 3 EMBARQ-CSU program in CSU and the registrational Phase 3 EMBARQ-ColdU and SD program in ColdU and SD.
Additional Celldex news items highlight expansion of the barzolvolimab program into prurigo nodularis and atopic dermatitis, as well as strategic decisions such as discontinuing development in eosinophilic esophagitis (EoE) after a Phase 2 study showed mast cell depletion without clinical benefit. Updates on CDX-622 provide insight into early-stage safety, pharmacokinetics and pharmacodynamics, including sustained reductions in serum tryptase in healthy volunteers.
Corporate news may feature quarterly financial results, leadership appointments and participation in healthcare and investor conferences. For readers tracking CLDX, this news stream offers a view into Celldex’s progress in mast cell biology, the evolution of its clinical pipeline and key regulatory and financial disclosures. Bookmarking this page allows ongoing access to company-issued press releases and related market-relevant developments.
Celldex Therapeutics announced the dosing of the first patient in its Phase 2 study of barzolvolimab for treating prurigo nodularis (PN). This humanized monoclonal antibody targets the KIT receptor tyrosine kinase, important for mast cell function, believed to drive chronic itch and neuroinflammation in PN. Earlier Phase 1b results showed significant clinical benefits with barzolvolimab, prompting this larger, double-blind, placebo-controlled study. The trial will assess the efficacy and safety of two dosing regimens in about 120 patients over 40 weeks, aiming to evaluate itch improvement and lesion healing. The study involves 50 global centers, including the U.S.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) reported Q1 2024 financial results and a corporate update. Phase 3 CSU studies to start in summer 2024. Positive Phase 2 CSU 12-week data presented at AAAAI 2024, with 52-week data to follow later. Phase 2 CIndU study enrollment completed, with Phase 2 PN study ongoing. Atopic dermatitis selected for Phase 2 study by YE 2024. Cash position at $823.8 million. Total revenue at $0.2 million. R&D expenses at $31.7 million. G&A expenses at $9.1 million. Net loss at $32.8 million.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.